{
    "601cb4541cb411341a000024_1": "Eosinophilic Gastritis",
    "601cb4541cb411341a000024_2": "eosinophilic gastritis and duodenitis",
    "601cb4541cb411341a000024_3": "eosinophilic gastritis and duodenitis",
    "590c74d170f9fc6f0f00001e_1": "Ecm22",
    "590c74d170f9fc6f0f00001e_2": "Upc2 and Ecm22",
    "590c74d170f9fc6f0f00001e_3": "Sut1",
    "590c74d170f9fc6f0f00001e_4": "Upc2 and Ecm22",
    "590c74d170f9fc6f0f00001e_5": "Ecm22",
    "590c74d170f9fc6f0f00001e_6": "Ste12",
    "590c74d170f9fc6f0f00001e_7": "Ecm22",
    "590c74d170f9fc6f0f00001e_8": "Ecm22",
    "5896271178275d0c4a000004_1": "respiratory distress syndrome",
    "5896271178275d0c4a000004_2": "respiratory distress syndrome",
    "5c8974bcd558e5f232000008_1": "Chiesi Pharma",
    "58d906b28acda3452900000d_1": "Xq28",
    "58d906b28acda3452900000d_2": "Xq28",
    "58d906b28acda3452900000d_3": "Xq28",
    "58d906b28acda3452900000d_4": "Xq28",
    "58d906b28acda3452900000d_5": "Xq28",
    "58d906b28acda3452900000d_6": "Xq28",
    "58d906b28acda3452900000d_7": "Xq28",
    "58d906b28acda3452900000d_8": "Xq28",
    "626aeba1e764a53204000040_1": "Ionis Pharmaceuticals",
    "5a43a139966455904c000008_1": "DNA methylation",
    "602a84ae1cb411341a000116_1": "Long noncoding RNAs",
    "602a84ae1cb411341a000116_2": "lncRNAs",
    "602a84ae1cb411341a000116_3": "lncRNAs",
    "602a84ae1cb411341a000116_4": "long non-coding RNAs (lncRNAs)",
    "602a84ae1cb411341a000116_5": "lncRNAs",
    "602a84ae1cb411341a000116_6": "lncRNAs",
    "56c1f009ef6e39474100003c_1": "Gaucher's disease",
    "56c1f009ef6e39474100003c_2": "Gaucher's disease",
    "53130a77e3eabad02100000f_1": "growth hormone",
    "53130a77e3eabad02100000f_2": "growth hormone",
    "53130a77e3eabad02100000f_3": "Growth hormone",
    "53130a77e3eabad02100000f_4": "growth hormone",
    "602343051cb411341a00008d_1": "apoC-III",
    "602343051cb411341a00008d_2": "apoC-III",
    "602343051cb411341a00008d_3": "apoC-III",
    "602343051cb411341a00008d_4": "apoC-III",
    "602343051cb411341a00008d_5": "APOC3",
    "602343051cb411341a00008d_6": "apoC-III",
    "5e5286036d0a277941000040_1": "chromosome 15",
    "5e5286036d0a277941000040_2": "chromosome 15",
    "5e5286036d0a277941000040_3": "chromosome 15",
    "5e5286036d0a277941000040_4": "chromosome 15",
    "56c1f020ef6e394741000047_1": "cortical dysplasia",
    "56c1f020ef6e394741000047_2": "cortical dysplasia",
    "56c1f020ef6e394741000047_3": "cortical dysplasia",
    "56c1f020ef6e394741000047_4": "meningioangiomatosis",
    "56c1f020ef6e394741000047_5": "cortical dysplasia",
    "56c1f020ef6e394741000047_6": "cortical dysplasia",
    "56c1f020ef6e394741000047_7": "cortical dysplasia",
    "56c1f020ef6e394741000047_8": "focal cortical dysplasia",
    "56c1f020ef6e394741000047_9": "focal cortical dysplasia",
    "56c1f020ef6e394741000047_10": "focal cortical dysplasia",
    "56c1f020ef6e394741000047_11": "cortical dysplasia",
    "56c1f020ef6e394741000047_12": "meningioangiomatosis",
    "56c1f020ef6e394741000047_13": "cortical dysplasia",
    "56c1f020ef6e394741000047_14": "cortical dysplasia",
    "58e74bff3e8b6dc87c000004_1": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_2": "Ribosomal protein genes RPS10",
    "58e74bff3e8b6dc87c000004_3": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_4": "Ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_5": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_6": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_7": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_8": "ribosomal protein genes",
    "58e74bff3e8b6dc87c000004_9": "Ribosomal protein genes RPS10",
    "56e857ae42442bac75000004_1": "zinc",
    "61f7ce26882a024a1000002d_1": "multiple myeloma",
    "61f7ce26882a024a1000002d_2": "multiple myeloma",
    "61f7ce26882a024a1000002d_3": "multiple myeloma",
    "61f7ce26882a024a1000002d_4": "Multiple Myeloma",
    "61f7ce26882a024a1000002d_5": "multiple myeloma",
    "61f7ce26882a024a1000002d_6": "multiple myeloma",
    "61f7ce26882a024a1000002d_7": "multiple myeloma",
    "61f7ce26882a024a1000002d_8": "multiple myeloma",
    "61f7ce26882a024a1000002d_9": "multiple myeloma",
    "61f7ce26882a024a1000002d_10": "multiple myeloma",
    "61f7ce26882a024a1000002d_11": "multiple myeloma",
    "61f7ce26882a024a1000002d_12": "multiple myeloma",
    "61f7ce26882a024a1000002d_13": "multiple myeloma",
    "61f7ce26882a024a1000002d_14": "multiple myeloma",
    "61f7ce26882a024a1000002d_15": "multiple myeloma",
    "6200411cc9dfcb9c09000014_1": "JUCHMME",
    "6200411cc9dfcb9c09000014_2": "JUCHMME",
    "6200411cc9dfcb9c09000014_3": "JUCHMME",
    "54f2210164850a5854000001_1": "eight cysteine residues that form four",
    "5a7428090384be9551000001_1": "pulmonary embolism",
    "5a7428090384be9551000001_2": "pulmonary embolism",
    "5a7428090384be9551000001_3": "pulmonary embolism",
    "5a7428090384be9551000001_4": "pulmonary embolism",
    "5a7428090384be9551000001_5": "pulmonary embolism",
    "5a7428090384be9551000001_6": "pulmonary embolism",
    "5a7428090384be9551000001_7": "pulmonary embolism",
    "5a7428090384be9551000001_8": "pulmonary embolism",
    "5e540c866d0a277941000052_1": "saracatinib",
    "5e540c866d0a277941000052_2": "saracatinib",
    "5c73ad367c78d69471000099_1": "platelet-derived growth factor receptor-\u03b1",
    "5c73ad367c78d69471000099_2": "platelet-derived growth factor receptor-\u03b1",
    "5c73ad367c78d69471000099_3": "platelet-derived growth factor receptor \u03b1",
    "5c73ad367c78d69471000099_4": "platelet-derived growth factor receptor-\u03b1",
    "5c73ad367c78d69471000099_5": "platelet-derived growth factor receptor \u03b1",
    "5c73ad367c78d69471000099_6": "platelet-derived growth factor receptor-\u03b1",
    "5c73ad367c78d69471000099_7": "PDGFR\u03b1",
    "5c8fe1f10101eac87000000a_1": "RUNX2 promotes astrocyte maturation.",
    "5e5438c3b761aafe09000003_1": "senktide",
    "53189656b166e2b80600001c_1": "alpha-synuclein",
    "53189656b166e2b80600001c_2": "alpha-synuclein",
    "53189656b166e2b80600001c_3": "alpha-synuclein",
    "53189656b166e2b80600001c_4": "alpha-synuclein",
    "53189656b166e2b80600001c_5": "alpha-synuclein",
    "53189656b166e2b80600001c_6": "alpha-synuclein",
    "53189656b166e2b80600001c_7": "alpha-synuclein",
    "53189656b166e2b80600001c_8": "alpha-synuclein",
    "53189656b166e2b80600001c_9": "Alpha-synuclein",
    "53189656b166e2b80600001c_10": "alpha-synuclein",
    "53189656b166e2b80600001c_11": "alpha-synuclein",
    "53189656b166e2b80600001c_12": "alpha-synuclein",
    "53189656b166e2b80600001c_13": "alpha-Synuclein",
    "53189656b166e2b80600001c_14": "alpha-Synuclein",
    "53189656b166e2b80600001c_15": "alpha-Synuclein",
    "53189656b166e2b80600001c_16": "alpha-synuclein",
    "53189656b166e2b80600001c_17": "alpha-synuclein",
    "53189656b166e2b80600001c_18": "alpha-synuclein",
    "53189656b166e2b80600001c_19": "alpha-synuclein",
    "53189656b166e2b80600001c_20": "alpha-synuclein",
    "53189656b166e2b80600001c_21": "alpha-synuclein",
    "53189656b166e2b80600001c_22": "alpha-synuclein",
    "53189656b166e2b80600001c_23": "alpha-synuclein",
    "532dcfc9d6d3ac6a34000021_1": "SET domain",
    "532dcfc9d6d3ac6a34000021_2": "SET domain",
    "532dcfc9d6d3ac6a34000021_3": "SET domain",
    "532dcfc9d6d3ac6a34000021_4": "SET domain",
    "532dcfc9d6d3ac6a34000021_5": "SET domain",
    "532dcfc9d6d3ac6a34000021_6": "SET domain",
    "532dcfc9d6d3ac6a34000021_7": "SET domain",
    "532dcfc9d6d3ac6a34000021_8": "SET domain",
    "532dcfc9d6d3ac6a34000021_9": "SET domain",
    "532dcfc9d6d3ac6a34000021_10": "SET domain",
    "532dcfc9d6d3ac6a34000021_11": "SET domain",
    "532dcfc9d6d3ac6a34000021_12": "catalytic SET domain",
    "532dcfc9d6d3ac6a34000021_13": "Meisetz (meiosis-induced factor containing a PR/SET domain",
    "532dcfc9d6d3ac6a34000021_14": "SET domain",
    "532dcfc9d6d3ac6a34000021_15": "SET domain",
    "532dcfc9d6d3ac6a34000021_16": "SET domain",
    "532dcfc9d6d3ac6a34000021_17": "SET domain",
    "532dcfc9d6d3ac6a34000021_18": "SET domain",
    "532dcfc9d6d3ac6a34000021_19": "SET domain",
    "532dcfc9d6d3ac6a34000021_20": "SET domain",
    "532dcfc9d6d3ac6a34000021_21": "SET domain",
    "532dcfc9d6d3ac6a34000021_22": "SET domain",
    "532dcfc9d6d3ac6a34000021_23": "SET domain",
    "52bf1f1303868f1b06000014_1": "Peroxiredoxin-2 (PRDX-2) is an antioxidant and chaperone-like protein critical for cell function.",
    "52bf1f1303868f1b06000014_2": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_3": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_4": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_5": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_6": "Peroxiredoxin 2 (Prx2) is an antioxidant enzyme that uses cysteine residues to decompose peroxides.",
    "52bf1f1303868f1b06000014_7": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_8": "antioxidant enzyme",
    "52bf1f1303868f1b06000014_9": "antioxidant enzymes",
    "603251f81cb411341a00013a_1": "c-Myc",
    "56c1f01def6e394741000045_1": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_2": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_3": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_4": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_5": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_6": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_7": "castration-resistant prostate cancer",
    "56c1f01def6e394741000045_8": "castration-resistant prostate cancer",
    "56c1f01def6e394741000045_9": "castration-resistant prostate cancer",
    "56c1f01def6e394741000045_10": "castration-resistant prostate cancer",
    "56c1f01def6e394741000045_11": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_12": "castration-resistant prostate cancer",
    "56c1f01def6e394741000045_13": "metastatic castration-resistant prostate cancer",
    "56c1f01def6e394741000045_14": "metastatic castration-resistant prostate cancer",
    "61f919cc882a024a10000048_1": "4660 participants from 218",
    "606ae4fd94d57fd879000056_1": "CYP2D6",
    "5e808ef4835f4e477700002a_1": "angiotensin II",
    "533be71dfd9a95ea0d000009_1": "H3K4",
    "533be71dfd9a95ea0d000009_2": "H3K4",
    "533be71dfd9a95ea0d000009_3": "H3K4",
    "533be71dfd9a95ea0d000009_4": "H3K4",
    "533be71dfd9a95ea0d000009_5": "H3K4",
    "533be71dfd9a95ea0d000009_6": "H3K4",
    "533be71dfd9a95ea0d000009_7": "H3K4",
    "533be71dfd9a95ea0d000009_8": "H3K4",
    "533be71dfd9a95ea0d000009_9": "H3K4",
    "533be71dfd9a95ea0d000009_10": "Lys4",
    "5fe3131ca43ad31278000048_1": "G+C content",
    "5fe3131ca43ad31278000048_2": "G+C content",
    "5d387c20a1e1595105000010_1": "78",
    "5d387c20a1e1595105000010_2": "18",
    "5c9791d2ecadf2e73f000026_1": "Cat fleas",
    "5c9791d2ecadf2e73f000026_2": "Ctenocephalides",
    "571f609c0fd6f91b6800000c_1": "\u03b2-galactosidase and \u03b2-hexosaminidase",
    "571f609c0fd6f91b6800000c_2": "\u03b2-galactosidase",
    "601ebde11cb411341a00005d_1": "signatureSearch",
    "601ebde11cb411341a00005d_2": "signatureSearch",
    "5e2a080caa19d7443100000a_1": "AMPK/Sirt1 pathway",
    "621ec0313a8413c65300005e_1": "cytotoxic drugs",
    "621ec0313a8413c65300005e_2": "Cytotoxic drugs",
    "56cae3eb5795f9a73e000021_1": "20 and 50 years",
    "601dbe2b1cb411341a00004d_1": "migraine",
    "601dbe2b1cb411341a00004d_2": "Migraine",
    "601dbe2b1cb411341a00004d_3": "acute treatment of migraine",
    "601dbe2b1cb411341a00004d_4": "migraine",
    "601dbe2b1cb411341a00004d_5": "acute migraine",
    "601dbe2b1cb411341a00004d_6": "cluster headache",
    "601dbe2b1cb411341a00004d_7": "migraine",
    "601dbe2b1cb411341a00004d_8": "migraine",
    "601dbe2b1cb411341a00004d_9": "migraine",
    "601dbe2b1cb411341a00004d_10": "acute oral treatment of migraine",
    "601dbe2b1cb411341a00004d_11": "headache",
    "601dbe2b1cb411341a00004d_12": "acute attacks of migraine",
    "601dbe2b1cb411341a00004d_13": "headache",
    "601dbe2b1cb411341a00004d_14": "migraine",
    "601dbe2b1cb411341a00004d_15": "migraine",
    "601dbe2b1cb411341a00004d_16": "migraine",
    "601dbe2b1cb411341a00004d_17": "migraine headache",
    "601dbe2b1cb411341a00004d_18": "migraine",
    "601dbe2b1cb411341a00004d_19": "migraine headache",
    "601dbe2b1cb411341a00004d_20": "migraine",
    "601dbe2b1cb411341a00004d_21": "migraine",
    "601dbe2b1cb411341a00004d_22": "migraine headache",
    "601dbe2b1cb411341a00004d_23": "cluster headache",
    "601dbe2b1cb411341a00004d_24": "cluster headache",
    "601dbe2b1cb411341a00004d_25": "migraine",
    "601dbe2b1cb411341a00004d_26": "migraine",
    "601dbe2b1cb411341a00004d_27": "acute treatment for migraine",
    "601dbe2b1cb411341a00004d_28": "acute treatment of migraine",
    "601dbe2b1cb411341a00004d_29": "migraine",
    "601dbe2b1cb411341a00004d_30": "migraine",
    "601dbe2b1cb411341a00004d_31": "acute migraine",
    "601dbe2b1cb411341a00004d_32": "migraine headache",
    "601dbe2b1cb411341a00004d_33": "migraine headache",
    "601dbe2b1cb411341a00004d_34": "acute oral migraine",
    "601dbe2b1cb411341a00004d_35": "migraine",
    "601dbe2b1cb411341a00004d_36": "migraine headache",
    "5fe3131fa43ad3127800004a_1": "TGF\u03b2",
    "5fe3131fa43ad3127800004a_2": "TGF\u03b2",
    "5fe3131fa43ad3127800004a_3": "TGF\u03b2",
    "5fe3131fa43ad3127800004a_4": "TGFbeta",
    "5e44b04c48dab47f26000016_1": "activin type II receptors",
    "5e44b04c48dab47f26000016_2": "activin type II receptors",
    "5e44b04c48dab47f26000016_3": "activin type II receptors",
    "5e44b04c48dab47f26000016_4": "activin type II receptors",
    "5e44b04c48dab47f26000016_5": "activin type II receptors",
    "5e44b04c48dab47f26000016_6": "activin type II receptors",
    "5e44b04c48dab47f26000016_7": "activin type II receptors",
    "5e44b04c48dab47f26000016_8": "activin type II receptors",
    "5e44b04c48dab47f26000016_9": "activin type II receptors",
    "5e44b04c48dab47f26000016_10": "activin type II receptors",
    "5e44b04c48dab47f26000016_11": "activin type II receptors",
    "5e44b04c48dab47f26000016_12": "activin type II receptors",
    "5e44b04c48dab47f26000016_13": "activin type II receptors",
    "5e44b04c48dab47f26000016_14": "activin type II receptors",
    "5e776443835f4e4777000008_1": "Astellas Pharma",
    "5e7641a0c6a8763d23000011_1": "Vaxchora",
    "5e7641a0c6a8763d23000011_2": "Vaxchora",
    "571f5c150fd6f91b68000009_1": "frataxin",
    "571f5c150fd6f91b68000009_2": "frataxin",
    "571f5c150fd6f91b68000009_3": "frataxin",
    "571f5c150fd6f91b68000009_4": "frataxin",
    "571f5c150fd6f91b68000009_5": "frataxin",
    "571f5c150fd6f91b68000009_6": "frataxin",
    "571f5c150fd6f91b68000009_7": "frataxin",
    "571f5c150fd6f91b68000009_8": "frataxin",
    "571f5c150fd6f91b68000009_9": "frataxin",
    "571f5c150fd6f91b68000009_10": "frataxin",
    "571f5c150fd6f91b68000009_11": "frataxin",
    "571f5c150fd6f91b68000009_12": "frataxin",
    "571f5c150fd6f91b68000009_13": "frataxin",
    "571f5c150fd6f91b68000009_14": "Frataxin",
    "571f5c150fd6f91b68000009_15": "frataxin",
    "571f5c150fd6f91b68000009_16": "frataxin",
    "571f5c150fd6f91b68000009_17": "frataxin",
    "571f5c150fd6f91b68000009_18": "frataxin",
    "571f5c150fd6f91b68000009_19": "frataxin",
    "571f5c150fd6f91b68000009_20": "frataxin",
    "57136a7e1174fb1755000006_1": "first trimester",
    "57136a7e1174fb1755000006_2": "first trimester",
    "57136a7e1174fb1755000006_3": "first trimester",
    "57136a7e1174fb1755000006_4": "first trimester",
    "57136a7e1174fb1755000006_5": "first trimester",
    "57136a7e1174fb1755000006_6": "first trimester",
    "587f795d92a5b8ad44000007_1": "Left-Right Asymmetry",
    "5a72302b2dc08e987e000005_1": "Patent foramen ovale",
    "5a72302b2dc08e987e000005_2": "patent foramen ovale",
    "5a72302b2dc08e987e000005_3": "patent foramen ovale",
    "6026ef311cb411341a0000d4_1": "Lundbeck",
    "624c838ee764a53204000001_1": "Alzheimer's disease",
    "624c838ee764a53204000001_2": "Alzheimer's disease",
    "624c838ee764a53204000001_3": "Alzheimer's disease",
    "587e07023ec846c24f000001_1": "PHYLUCE",
    "587e07023ec846c24f000001_2": "PHYLUCE",
    "587e07023ec846c24f000001_3": "PHYLUCE",
    "554356d0ed966d112c000005_1": "delta-distance",
    "554356d0ed966d112c000005_2": "delta-distance",
    "554356d0ed966d112c000005_3": "delta-distance",
    "554356d0ed966d112c000005_4": "Mahalanobis distance",
    "554356d0ed966d112c000005_5": "delta-distance",
    "554356d0ed966d112c000005_6": "delta-distance",
    "5a7d5ce0faa1ab7d2e00001b_1": "obesity",
    "61f7d683882a024a10000036_1": "stearoyl-CoA desaturase 1",
    "61f7d683882a024a10000036_2": "stearoyl-CoA desaturase 1",
    "61f7d683882a024a10000036_3": "stearoyl-CoA desaturase 1",
    "61f7d683882a024a10000036_4": "stearoyl-CoA desaturase 1",
    "60527e8c94d57fd879000012_1": "phase IV",
    "56ffdc1ccf1c32585100000b_1": "A-to-I editing, in which adenosine is deaminated to inosine",
    "56ffdc1ccf1c32585100000b_2": "A-to-I",
    "56ffdc1ccf1c32585100000b_3": "A-to-I",
    "56ffdc1ccf1c32585100000b_4": "A-to-I",
    "56ffdc1ccf1c32585100000b_5": "adenosine-to-inosine",
    "56ffdc1ccf1c32585100000b_6": "adenosine residue is base-modified to inosine",
    "56ffdc1ccf1c32585100000b_7": "adenosine is deaminated to inosine",
    "56ffdc1ccf1c32585100000b_8": "inosine",
    "56ffdc1ccf1c32585100000b_9": "A-to-I editing, in which adenosine is deaminated to inosine",
    "56ffdc1ccf1c32585100000b_10": "adenosine",
    "5a7d6287faa1ab7d2e00001c_1": "GDNF family receptor \u03b1-like (GFRAL)",
    "5abcf0b0fcf4565872000024_1": "Leishmania species",
    "5abcf0b0fcf4565872000024_2": "Leishmania species causing cutaneous leishmaniasis (CL) are more sensitive to Sb(III) than the species responsible for visceral leishmaniasis (VL).",
    "5abcf0b0fcf4565872000024_3": "Leishmania viannia braziliensis",
    "5abcf0b0fcf4565872000024_4": "Leishmania species",
    "550c4011a103b78016000009_1": "serine 129",
    "550c4011a103b78016000009_2": "serine 129",
    "550c4011a103b78016000009_3": "serine 129",
    "550c4011a103b78016000009_4": "serine 129",
    "550c4011a103b78016000009_5": "serine 129",
    "550c4011a103b78016000009_6": "serine 129",
    "56d19a363975bb303a000017_1": "MDM two binding protein (MTBP)",
    "56d19a363975bb303a000017_2": "MDM two binding protein (MTBP)",
    "56d19a363975bb303a000017_3": "DNA replication factor that is regulated by cyclin-dependent kinases and the DNA damage checkpoint. We identified MDM two binding protein (MTBP)",
    "620c28d03a8413c653000007_1": "myeloid leukaemia",
    "5ad6e431133db5eb7800000e_1": "Ishihara test",
    "5ad6e431133db5eb7800000e_2": "Ishihara",
    "5ad6e431133db5eb7800000e_3": "Ishihara Test",
    "5321bc309b2d7acc7e00000d_1": "PI3K-\u03b4",
    "5e319789fbd6abf43b00004a_1": "BRAF",
    "5e319789fbd6abf43b00004a_2": "novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF",
    "5e319789fbd6abf43b00004a_3": "BRAF",
    "5e319789fbd6abf43b00004a_4": "BRAF",
    "5e319789fbd6abf43b00004a_5": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_6": "BRAF",
    "5e319789fbd6abf43b00004a_7": "BRAF",
    "5e319789fbd6abf43b00004a_8": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_9": "BRAF",
    "5e319789fbd6abf43b00004a_10": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_11": "BRAF",
    "5e319789fbd6abf43b00004a_12": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_13": "BRAF",
    "5e319789fbd6abf43b00004a_14": "BRAF",
    "5e319789fbd6abf43b00004a_15": "BRAF",
    "5e319789fbd6abf43b00004a_16": "BRAF",
    "5e319789fbd6abf43b00004a_17": "BRAF",
    "5e319789fbd6abf43b00004a_18": "BRAF",
    "5e319789fbd6abf43b00004a_19": "binimetinib",
    "5e319789fbd6abf43b00004a_20": "BRAF",
    "5e319789fbd6abf43b00004a_21": "BRAF",
    "5e319789fbd6abf43b00004a_22": "binimetinib",
    "5e319789fbd6abf43b00004a_23": "BRAF V600-mutated melanoma",
    "5e319789fbd6abf43b00004a_24": "BRAF",
    "5e319789fbd6abf43b00004a_25": "BRAF",
    "5e319789fbd6abf43b00004a_26": "BRAF",
    "5e319789fbd6abf43b00004a_27": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_28": "BRAF/MEK",
    "5e319789fbd6abf43b00004a_29": "BRAFV600E",
    "5e319789fbd6abf43b00004a_30": "BRAF",
    "5e319789fbd6abf43b00004a_31": "MET",
    "5e319789fbd6abf43b00004a_32": "C-KIT",
    "5e319789fbd6abf43b00004a_33": "BRAF V600E kinase",
    "5e319789fbd6abf43b00004a_34": "BRAF",
    "5e319789fbd6abf43b00004a_35": "BRAF",
    "5e319789fbd6abf43b00004a_36": "BRAF",
    "5a89800efcd1d6a10c00000c_1": "A secreted enzyme, PM20D1, enriched in UCP1+ adipocytes, exhibits catalytic and hydrolytic activity to reversibly form N-acyl amino acids.",
    "5319ac36b166e2b806000031_1": "GIT1",
    "5319ac36b166e2b806000031_2": "Rac1",
    "6217db1b3a8413c653000027_1": "haemophagocytic lymphohistiocytosis",
    "5a9d8a651d1251d03b00001f_1": "Mini-BioArchive system",
    "56f961b3cf1c325851000003_1": "blue",
    "56f961b3cf1c325851000003_2": "blue",
    "5139b31dbee46bd34c000004_1": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_2": "experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_3": "Experimental Autoimmune Encephalomyelitis",
    "5139b31dbee46bd34c000004_4": "Experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_5": "experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_6": "experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_7": "Experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_8": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_9": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_10": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_11": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_12": "Experimental autoimmune encephalomyelitis (EAE)",
    "5139b31dbee46bd34c000004_13": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_14": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_15": "experimental autoimmune encephalomyelitis",
    "5139b31dbee46bd34c000004_16": "EAE",
    "553ca8d8f32186855800000d_1": "replication defects",
    "58e9f0ba3e8b6dc87c00000e_1": "Sulcia muelleri",
    "5a6e2578b750ff445500003d_1": "diffloop",
    "5a6e2578b750ff445500003d_2": "diffloop",
    "5a6e2578b750ff445500003d_3": "diffloop",
    "5a6e2578b750ff445500003d_4": "diffloop",
    "5a6e2578b750ff445500003d_5": "diffloop",
    "5e29fb27aa19d74431000005_1": "hyperphosphorylation of DDR proteins (BRCA1, Chk2, and \u03b3H2AX), altered the chronology and persistence of JNK",
    "5c6e0f537c78d6947100004a_1": "tropomyosin receptor kinases",
    "58dbb8968acda3452900001b_1": "Sudden Unexpected Death in Epilepsy",
    "58dbb8968acda3452900001b_2": "sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_3": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_4": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_5": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_6": "epilepsy",
    "58dbb8968acda3452900001b_7": "Epilepsy",
    "58dbb8968acda3452900001b_8": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_9": "Epilepsy",
    "58dbb8968acda3452900001b_10": "Epilepsy",
    "58dbb8968acda3452900001b_11": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_12": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_13": "epilepsy",
    "58dbb8968acda3452900001b_14": "epilepsy",
    "58dbb8968acda3452900001b_15": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_16": "sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_17": "Epilepsy",
    "58dbb8968acda3452900001b_18": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_19": "sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_20": "sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_21": "Sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_22": "sudden unexpected death in epilepsy",
    "58dbb8968acda3452900001b_23": "sudden unexpected death in epilepsy",
    "5a87f44061bb38fb2400000f_1": "cancer",
    "6057bf0694d57fd879000031_1": "apoE4-165",
    "6057bf0694d57fd879000031_2": "a specific apoE4 fragment, apoE4-165,",
    "6057bf0694d57fd879000031_3": "a specific apoE4 fragment, apoE4-165,",
    "6057bf0694d57fd879000031_4": "apoE4-165",
    "606b75c194d57fd87900006c_1": "2017",
    "571cdd227de986d80d00000f_1": "Yersinia pestis",
    "621d02f33a8413c653000047_1": "mechanotransduction process and can transduce mechanical signals into biological signals by mediating Ca2+ influx, which in turn regulates cytoskeletal remodeling and stress alterations.",
    "6032899c1cb411341a000144_1": "Integrins are transmembrane glycoproteins that are broadly distributed in living organisms.",
    "6057c2f894d57fd879000033_1": "EpiMethylTag",
    "6057c2f894d57fd879000033_2": "EpiMethylTag",
    "6057c2f894d57fd879000033_3": "EpiMethylTag",
    "6057c2f894d57fd879000033_4": "EpiMethylTag",
    "6057c2f894d57fd879000033_5": "EpiMethylTag",
    "5ebac76b0d431b5f7300000d_1": "H3K9me",
    "5ebac76b0d431b5f7300000d_2": "H3K9me",
    "5c632cc1e842deac6700000f_1": "primary ovarian insufficiency",
    "5c632cc1e842deac6700000f_2": "Primary ovarian insufficiency (POI)",
    "5c632cc1e842deac6700000f_3": "primary ovarian insufficiency",
    "5c632cc1e842deac6700000f_4": "primary ovarian insufficiency",
    "5c632cc1e842deac6700000f_5": "A homozygous NOBOX truncating variant causes defective transcriptional activation and leads to primary ovarian insufficiency.",
    "5c632cc1e842deac6700000f_6": "that POI is",
    "5c632cc1e842deac6700000f_7": "POI",
    "56c1f003ef6e394741000039_1": "orexin receptor",
    "56c1f003ef6e394741000039_2": "orexin receptor",
    "56c1f003ef6e394741000039_3": "orexin receptor",
    "56c1f003ef6e394741000039_4": "Orexin receptor",
    "56c1f003ef6e394741000039_5": "orexin",
    "56c1f003ef6e394741000039_6": "orexin",
    "56c1f003ef6e394741000039_7": "orexin receptor",
    "56c1f003ef6e394741000039_8": "orexin receptor",
    "56c1f003ef6e394741000039_9": "orexin",
    "56c1f003ef6e394741000039_10": "orexin (hypocretin) system",
    "5a70d42899e2c3af26000002_1": "SLC2A10",
    "5a70d42899e2c3af26000002_2": "SLC2A10",
    "5a70d42899e2c3af26000002_3": "SLC2A10",
    "5a70d42899e2c3af26000002_4": "SLC2A10",
    "5a70d42899e2c3af26000002_5": "SLC2A10",
    "58da1aa08acda34529000012_1": "hCG",
    "58da1aa08acda34529000012_2": "hCG",
    "622b9d593a8413c653000095_1": "prostate cancer",
    "622b9d593a8413c653000095_2": "prostate",
    "622b9d593a8413c653000095_3": "prostate",
    "622b9d593a8413c653000095_4": "prostate",
    "622b9d593a8413c653000095_5": "prostate",
    "622b9d593a8413c653000095_6": "prostate",
    "622b9d593a8413c653000095_7": "prostate",
    "622b9d593a8413c653000095_8": "prostate",
    "622b9d593a8413c653000095_9": "prostate",
    "622b9d593a8413c653000095_10": "prostate",
    "622b9d593a8413c653000095_11": "prostate",
    "622b9d593a8413c653000095_12": "prostate",
    "622b9d593a8413c653000095_13": "prostate",
    "622b9d593a8413c653000095_14": "prostate",
    "622b9d593a8413c653000095_15": "prostate",
    "622b9d593a8413c653000095_16": "prostate",
    "622b9d593a8413c653000095_17": "prostate",
    "622b9d593a8413c653000095_18": "prostate",
    "622b9d593a8413c653000095_19": "prostate",
    "516e7fda298dcd4e51000081_1": "adenosylmethionine",
    "516e7fda298dcd4e51000081_2": "methionine",
    "516e7fda298dcd4e51000081_3": "methionine",
    "516e7fda298dcd4e51000081_4": "adenosylmethionine",
    "516e7fda298dcd4e51000081_5": "S-adenosylmethionine",
    "516e7fda298dcd4e51000081_6": "S-Adenosyl methionine",
    "516e7fda298dcd4e51000081_7": "S-adenosyl-l-methionine",
    "516e7fda298dcd4e51000081_8": "SAM",
    "516e7fda298dcd4e51000081_9": "S-adenosyl-l-methionine",
    "516e7fda298dcd4e51000081_10": "SAM",
    "516e7fda298dcd4e51000081_11": "S-adenosylmethionine",
    "516e7fda298dcd4e51000081_12": "S-adenosyl-L-methionine",
    "602598101cb411341a0000ae_1": "biological and targeted synthetic disease-modifying antirheumatic drugs",
    "626aeab6e764a5320400003e_1": "In May 2019",
    "601db60e1cb411341a000049_1": "chromosome D2",
    "601db60e1cb411341a000049_2": "chromosome D2",
    "601db60e1cb411341a000049_3": "chromosome D2",
    "5c61f767e842deac67000007_1": "Telomerecat",
    "5c61f767e842deac67000007_2": "Telomerecat",
    "5c61f767e842deac67000007_3": "Telomerecat",
    "550c3d45a103b78016000008_1": "Alpha-synuclein",
    "550c3d45a103b78016000008_2": "The",
    "550c3d45a103b78016000008_3": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease,",
    "550c3d45a103b78016000008_4": "alpha-Synuclein, the main component of LBs,",
    "550c3d45a103b78016000008_5": "alpha-synuclein",
    "550c3d45a103b78016000008_6": "Lewy neurites, the defining neuropathological characteristics of Parkinson's disease and dementia with Lewy bodies.",
    "550c3d45a103b78016000008_7": "the main component of Lewy body is alpha-synuclein.",
    "550c3d45a103b78016000008_8": "alpha-synuclein.",
    "550c3d45a103b78016000008_9": "The main component of Lewy bodies is alpha-synuclein.",
    "550c3d45a103b78016000008_10": "The main component of Lewy bodies is alpha-synuclein (AS).",
    "550c3d45a103b78016000008_11": "Lewy bodies.",
    "550c3d45a103b78016000008_12": "Alpha-synuclein, a main component of Lewy bodies in synucleinopathies and senile plaques in Alzheimer disease, is centrally involved in neurodegeneration.",
    "550c3d45a103b78016000008_13": "The main component of Lewy bodies is alpha-synuclein.",
    "550c3d45a103b78016000008_14": "alpha-synuclein.",
    "550c3d45a103b78016000008_15": "alpha-Synuclein, the main component of LBs,",
    "550c3d45a103b78016000008_16": "Lewy bodies and dystrophic neurites; alpha-synuclein also accumulates in the cytoplasm of glial cells",
    "550c3d45a103b78016000008_17": "the inclusion bodies are referred to as Lewy bodies and",
    "550c3d45a103b78016000008_18": "The",
    "550c3d45a103b78016000008_19": "alpha-Synuclein, the main component of LBs,",
    "550c3d45a103b78016000008_20": "two Lewy body protein components that may",
    "550c3d45a103b78016000008_21": "Lewy neurites",
    "550c3d45a103b78016000008_22": "Alpha-synuclein (AS) is the main component of Lewy bodies and",
    "550c3d45a103b78016000008_23": "alpha-synuclein antiaggregatory agents for dementia with Lewy bodies.",
    "5c7aae9dd774d0424000000a_1": "activation of type I interferons in response to cytosolic nucleic acid ligands. Recent evidence indicates involvement of the STING pathway in the induction of antitumor immune response.",
    "62005e02c9dfcb9c09000018_1": "MBPpred",
    "62005e02c9dfcb9c09000018_2": "MBPpred",
    "603219c21cb411341a000133_1": "DNA transfer involving extracellular vesicles is still under appreciated.",
    "601bde6e1cb411341a000006_1": "Multisystem Disease with Abnormal Neurodevelopment",
    "5aacd487fcf4565872000007_1": "POLQ gene",
    "58a2df9c60087bc10a000006_1": "8%",
    "5c910ae0ecadf2e73f000007_1": "Bristol-Myers Squibb"
}
